ArticleFrontiers in microbiology2025
Genomic epidemiology and anti-biofilm mechanisms of Lactobacillus in ST11 carbapenem-resistant
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Vegetable Juice Fermented with Lactiplantibacillus plantarum WB3813 and Lactiplantibacillus plantarum WB3814 Alleviates HProbiotics and antimicrobial proteins · 2026Article
- Isolation and Mechanistic Characterization ofFoods (Basel, Switzerland) · 2026Article
- Emergence of a KL239-OCL6-ST63 Carbapenem-Resistant Acinetobacter pittii Strain, Co-carrying blaCurrent microbiology · 2026Article
- Clinical Distribution Characteristics and Antimicrobial Resistance Trends ofInfection and drug resistance · 2026Article
- Genomic and Phenotypic Characterization of Two High-RiskAntibiotics (Basel, Switzerland) · 2025Article
- Distribution Features and Antimicrobial Resistance Trends of Clinical Pathogens: A Retrospective Study in a Tertiary Teaching Hospital in East China (2020-2024).Infection and drug resistance · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ST11 clone of carbapenem-resistant Methods: To address this issue, we conducted an integrated genomic epidemiological and metabolomic study of ST11 CRKP isolates collected from 13 hospitals in eastern and central China between 2014 and 2020. A total of 2,805 clinical isolates were screened, and 334 ST11 strains were identified using MALDI-TOF mass spectrometry and whole-genome sequencing. Biofilm formation was assessed through microtiter plate assays, while co-culture experiments with Lactobacillus fermentum and Lactobacillus gasseri were performed to evaluate anti-biofilm activity. Scanning electron microscopy (SEM) and non-targeted metabolomics were used to explore structural and metabolic changes. Results: Genomic analysis revealed alarming resistance rates exceeding 90% to Conclusion: This study reveals critical insights into the clonal spread and biofilm-associated metabolic vulnerabilities of ST11 CRKP. The findings highlight the therapeutic potential of Lactobacillus-based interventions and pave the way for novel probiotic-assisted and plasmid-targeted strategies against antimicrobial-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.